What is HUMAW's health score?

Humacyte, Inc. (HUMAW) has a TradeApes health score of 38 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is HUMAW's estimated fair value?

Based on our 5-year discounted cash flow model, Humacyte, Inc.'s estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is HUMAW undervalued or overvalued?

Our model currently rates HUMAW as Fair Value. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for HUMAW... Refresh in a moment for the full analysis.

Humacyte, Inc. (HUMAW)

Healthcare Fair Value High weak

Updated: 2026-04-21

TradeApes Score

reduce

Financial Strength

50 Mixed

Operating Trend

40 Weak

Relative Value

40 Weak

Capital Allocation

10 Stressed

Risk

35 Weak

Key Findings

+ Low leverage — net debt/EBITDA below 1×

Unlock Full Report →

− Significant dilution — share count up more than 5% year over year

Unlock Full Report →

3 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.